Key Takeaway: PTC Therapeutics, Inc. announced a conference call scheduled for November 4, 2025, to discuss its third quarter financial results and provide a business update. The call will be accessible via phone and webcast, with a replay available afterward. The company emphasizes its commitment to developing treatments for rare disorders.
Price reaction · baseline $68.36 (2025-10-20 close) · hit pre-market · clean, no other PTCT news in the window
day 0 close · peak
-1.7%
Market Sentiment Analysis
POSITIVE FACTORS
PTC Therapeutics is actively engaging with investors through a conference call.
The company is providing updates on its financial results and business outlook.
PTC is committed to addressing unmet medical needs with its pipeline.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+74%
120-day peak, hindsight
Typical move
6.6%
average across 4 past catalysts
Lead asset
Ataluren
Phase 3 · Cystic Fibrosis
Full Press Release Details
WARREN, N.J.,Oct. 21, 2025/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its third quarter 2025 financial results and provide an update on the company's business and outlook on Tuesday, November 4, at 4:30 p.m. ET.
To access the call by phone, pleaseclick hereto register, and you will be provided with dial-in details. To avoid delays, we recommend that participants dial in for the conference call 15 minutes before the start of the call. The webcast conference call can be accessed on the Investors section of the PTC website athttps://ir.ptcbio.com/events-presentations. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for 30 days.
ABOUT PTC THERAPEUTICS, INC.PTC is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visitwww.ptcbio.comand follow on Facebook, X, and LinkedIn.